Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.
Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.
